Clinical trial design for peptide therapeutics requires consideration of their unique pharmacokinetic profiles, immunogenicity potential, and route of administration. This guide covers trial design across all phases.
| Phase | Duration | Population | Cost |
|---|
| Preclinical | 2–5 years | Animals | $2–10M |
| Phase I | 6–12 months | 20–80 HV/patients | $5–15M |
| Phase II | 1–3 years | 100–300 patients | $20–50M |
| Phase III | 2–4 years | 1000–5000+ patients | $100–500M |
| Phase IV | Ongoing | Post-market | Variable |
| Factor | Impact | Mitigation |
|---|
| Short half-life | Frequent dosing | Formulation optimization |
| Immunogenicity | Reduced efficacy, safety | T-cell epitope elimination |
| Oral bioavailability | Limited to injection | Oral formulations (SNAC) |
| Aggregation | Reduced potency | Stabilizers, PEGylation |
| Metabolic instability | Rapid clearance | D-amino acid substitution |
Objectives:
- Safety and tolerability
- Pharmacokinetics (PK)
- Pharmacodynamics (PD)
- Maximum tolerated dose (MTD)
| Component | Typical Approach |
|---|
| Design | Randomized, double-blind, placebo-controlled |
| Dose levels | 3–5 (SAD), 2–3 (MAD) |
| Cohort size | 6–10 per cohort |
| Starting dose | 1/10th NOAEL (preclinical) |
| Escalation | Modified Fibonacci or BOIN design |
| Endpoints | Safety, PK, PD biomarkers |
Rule of 3: If 0/3 patients experience DLT, escalate to next dose. If 1/3, expand to 6. If ≥2/6, MTD reached.
BOIN (Bayesian Optimal Interval): More efficient than 3+3, same operating characteristics.
| PK Parameter | Method | Requirement |
|---|
| C_max | Model-independent | Multiple time points |
| T_max | Model-independent | Multiple time points |
| AUC | Model-independent | Full PK profile |
| t₁/₂ | Model-dependent | Elimination phase |
| CL/F | Model-dependent | From AUC |
| Vd/F | Model-dependent | From CL and t₁/₂ |
| Aspect | Details |
|---|
| Population | 50–100 patients |
| Duration | 4–12 weeks |
| Endpoints | Primary PD biomarker, preliminary efficacy |
| Design | Randomized, controlled, 2–3 dose groups |
| Aspect | Details |
|---|
| Population | 100–300 patients |
| Duration | 12–24 weeks |
| Endpoints | Clinical efficacy, dose-response |
| Design | Randomized, double-blind, 3–5 dose groups + placebo |
| Statistics | MCP-Mod (multiple comparison procedure – modelling) |
Advantages:
- Flexible sample size re-estimation
- Dose selection optimization
- Futility stopping
Methods:
- Group sequential design
- Sample size re-estimation
- Dose selection adaptation
| Component | FDA Requirement | EMA Requirement |
|---|
| Population | Adequate representation | Adequate representation |
| Control | Placebo or active | Placebo or active |
| Duration | Sufficient for efficacy | Sufficient for efficacy |
| Endpoints | Clinically meaningful | Clinically meaningful |
| Statistics | Pre-specified, two adequate studies | Pre-specified, two adequate studies |
| Endpoint Type | Examples | Regulatory Acceptance |
|---|
| Primary efficacy | HbA1c (diabetes), weight (obesity) | FDA/EMA accepted |
| Co-primary | Multiple endpoints | Rarely used |
| Surrogate | Biomarkers (accelerated approval) | Limited |
| Patient-reported outcomes | Quality of life, symptom scores | Supplementary |
Formula:
Where:
- α = Type I error (usually 0.05)
- β = Type II error (usually 0.20, power = 80%)
- σ = standard deviation
- δ = clinically meaningful difference
| Route | Trial Considerations |
|---|
| Subcutaneous | Injection site reactions, bioavailability |
| Intramuscular | Pain, absorption variability |
| Intravenous | Infusion reactions, hospital setting |
| Oral | Food effects, absorption enhancers |
| Nasal | Local tolerability, absorption |
Required assessments:
- Anti-drug antibody (ADA) testing at baseline and regular intervals
- Neutralizing antibody (NAb) testing if ADA positive
- Impact on PK, efficacy, safety
Timing: Baseline, 4 weeks, 8 weeks, then every 3 months
Peptide-specific adjustments:
- Renal impairment: Reduce dose or extend interval
- Hepatic impairment: Minimal adjustment (most peptides)
- Weight-based dosing: For obesity/diabetes peptides
- Titration: Gradual dose escalation to minimize GI effects
| Population | Definition | Use |
|---|
| ITT | All randomized | Primary efficacy |
| mITT | All treated with ≥1 dose | Safety |
| PP | Completed per protocol | Sensitivity |
| Method | Application |
|---|
| Bonferroni | Conservative, simple |
| Holm | Step-down, less conservative |
| Hochberg | Step-up, less conservative |
| Graphical approach | Complex gatekeeping |
- O’Brien-Fleming boundaries: Conservative early stopping
- Lan-DeMets alpha spending: Flexible timing
- Futility analysis: Conditional power <20% → stop
| Category | Definition | Action |
|---|
| SAE | Death, life-threatening, hospitalization | Report within 24 hr |
| SUSAR | Related SAE, unexpected | Expedited reporting |
| AESI | Adverse event of special interest | Protocol-specified |
| ADR | Drug-related adverse event | Causality assessment |
Composition: Independent physicians, statisticians, ethicists
Responsibilities:
- Review unblinded safety data
- Recommend study modifications
- Ensure participant safety
| Type | Purpose | Example |
|---|
| Diagnostic | Patient selection | HbA1c ≥7% |
| Prognostic | Risk stratification | Baseline weight |
| Predictive | Treatment response | ADA status |
| Pharmacodynamic | Drug effect | GLP-1 receptor activation |
Biomarker qualification:
- Analytical validation (accuracy, precision)
- Clinical validation (clinical utility)
- Regulatory qualification (EMA/FDA)
| Type | Purpose | Timeline |
|---|
| Pre-IND (Type B) | Discuss Phase I design | 60-day request |
| End-of-Phase I (Type B) | Discuss Phase II plan | 60-day request |
| End-of-Phase II (Type B) | Discuss Phase III design | 60-day request |
| Pre-NDA/BLA (Type B) | Discuss submission | 60-day request |
| Type A | Serious safety issues | 30-day request |
| Study | Purpose | Timeline |
|---|
| REMS | Risk management | Per approval |
| Post-marketing commitment | Additional data | 1–5 years |
| Long-term safety | Safety surveillance | 3–10 years |
- FDA. Guidance for Industry: E6 Good Clinical Practice. 2017.
- EMA. Guideline on the choice of the non-inferiority margin. CPMP/EWP/2158/99.
- ICH E9(R1). Addendum on Estimands and Sensitivity Analysis.
4.ICH E20. Adaptive Clinical Trials.
